Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 2/2009

01-01-2009 | Original Article

Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?

Authors: Richard M. Logan, Andrea M. Stringer, Joanne M. Bowen, Rachel J. Gibson, Stephen T. Sonis, Dorothy M. K. Keefe

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2009

Login to get access

Abstract

Purpose

Alimentary tract (AT) mucositis is a serious problem complicating cancer treatment, however, its pathobiology remains incompletely understood. Nuclear factor-κB (NF-κB) and pro-inflammatory cytokines are considered to have important roles in its development. This has been previously demonstrated in different sites of the AT following administration of irinotecan in an animal model using the Dark Agouti rat. The aim of the present study was to determine whether the changes that occur in the AT are affected by the type of mucotoxic drug.

Methods

Female DA rats were given a single dose of either methotrexate (1.5 mg/kg intramuscularly) or 5-fluorouracil (150 mg/kg intraperitoneally). Rats were killed at 30, 60, 90 min, 2, 6, 12, 24, 48 and 72 h. Control rats received no treatment. Samples of oral mucosa, jejunum and colon were collected. Haematoxylin and eosin stained sections were examined with respect to histological evidence of damage and standard immunohistochemical techniques were used to demonstrate tissue expression of NF-κB, TNF, IL-1β and IL-6.

Results

Both MTX and 5-FU administration caused histological evidence of tissue damage in the AT as well as changes in tissue expression of NF-κB and specific pro-inflammatory cytokines. This study, however, demonstrated that there were differences in the timing of histological changes as well as the timing and intensity of pro-inflammatory cytokine tissue expression caused by the different drugs.

Conclusions

The results from this study suggest that there are differences in the mucositis pathobiology caused by different drugs. This may have important ramifications for the management of mucositis particularly with respect to the development of treatment regimens for mucositis. Further investigations are required to determine the exact pathways that lead to damage caused by the different drugs.
Literature
1.
go back to reference Anthony L, Bowen J, Garden A et al (2006) New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer 14:516–518PubMedCrossRef Anthony L, Bowen J, Garden A et al (2006) New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer 14:516–518PubMedCrossRef
2.
go back to reference Aota K, Azuma M, Yamashita T et al (2000) 5-Fluorouracil induces apoptosis through the suppression of NF-[kappa]B activity in human salivary gland cancer cells. Biochem Biophys Res Commun 273:1168–1174PubMedCrossRef Aota K, Azuma M, Yamashita T et al (2000) 5-Fluorouracil induces apoptosis through the suppression of NF-[kappa]B activity in human salivary gland cancer cells. Biochem Biophys Res Commun 273:1168–1174PubMedCrossRef
3.
go back to reference Azuma M, Yamashita T, Aota K et al (2001) 5-Fluorouracil suppression of NF-[kappa]B is mediated by the inhibition of I[kappa]B kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282:292–296PubMedCrossRef Azuma M, Yamashita T, Aota K et al (2001) 5-Fluorouracil suppression of NF-[kappa]B is mediated by the inhibition of I[kappa]B kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282:292–296PubMedCrossRef
4.
go back to reference Bowen JM, Gibson RJ, Keefe DM et al (2005) Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37:56–62PubMedCrossRef Bowen JM, Gibson RJ, Keefe DM et al (2005) Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37:56–62PubMedCrossRef
5.
go back to reference Carneiro-Filho BA, Lima IP, Araujo DH et al (2004) Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci 49:65–72PubMedCrossRef Carneiro-Filho BA, Lima IP, Araujo DH et al (2004) Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci 49:65–72PubMedCrossRef
6.
go back to reference Carneiro-Filho BA, Oria RB, Wood Rea K et al (2004) Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice. Nutrition 20:934–941PubMedCrossRef Carneiro-Filho BA, Oria RB, Wood Rea K et al (2004) Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice. Nutrition 20:934–941PubMedCrossRef
7.
go back to reference Cool JC, Dyer JL, Xian CJ et al (2005) Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Hormone IGF Res 15:72–82CrossRef Cool JC, Dyer JL, Xian CJ et al (2005) Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Hormone IGF Res 15:72–82CrossRef
8.
go back to reference de Koning BA, Sluis M, Lindenbergh-Kortleve DJ et al (2007) Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 210:144–152PubMedCrossRef de Koning BA, Sluis M, Lindenbergh-Kortleve DJ et al (2007) Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 210:144–152PubMedCrossRef
9.
go back to reference Elting LS, Cooksley C, Chambers MS et al (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539PubMedCrossRef Elting LS, Cooksley C, Chambers MS et al (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539PubMedCrossRef
10.
go back to reference Gibson RJ, Bowen JM, Cummins AG et al (2005) Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 4:188–195PubMedCrossRef Gibson RJ, Bowen JM, Cummins AG et al (2005) Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 4:188–195PubMedCrossRef
11.
go back to reference Gibson RJ, Keefe DM, Thompson FM et al (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751–2757PubMedCrossRef Gibson RJ, Keefe DM, Thompson FM et al (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751–2757PubMedCrossRef
12.
go back to reference Jones J, Avritscher E, Cooksley C et al (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer V14:505–515CrossRef Jones J, Avritscher E, Cooksley C et al (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer V14:505–515CrossRef
13.
go back to reference Keefe D, Schubert M, Elting L et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef Keefe D, Schubert M, Elting L et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef
14.
15.
go back to reference Krajewska M, Wang HG, Krajewski S et al (1997) Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 57:1605–1613PubMed Krajewska M, Wang HG, Krajewski S et al (1997) Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 57:1605–1613PubMed
16.
go back to reference Krajewska M, Zapata JM, Meinhold-Heerlein I et al (2002) Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4:129–140PubMedCrossRef Krajewska M, Zapata JM, Meinhold-Heerlein I et al (2002) Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4:129–140PubMedCrossRef
17.
go back to reference Krajewski S, Krajewska M, Reed JC (1996) Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 56:2849–2855PubMed Krajewski S, Krajewska M, Reed JC (1996) Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 56:2849–2855PubMed
18.
19.
go back to reference Leitão RFC, Ribeiro RA, Bellaguarda EAL et al (2008) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 61:215–222PubMedCrossRef Leitão RFC, Ribeiro RA, Bellaguarda EAL et al (2008) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 61:215–222PubMedCrossRef
20.
go back to reference Logan RM, Gibson RJ, Bowen JM et al (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (in press) Logan RM, Gibson RJ, Bowen JM et al (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (in press)
21.
go back to reference Logan RM, Stringer AM, Bowen JM et al (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33:448–460PubMedCrossRef Logan RM, Stringer AM, Bowen JM et al (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33:448–460PubMedCrossRef
22.
go back to reference Majumdar S, Aggarwal BB (2001) Methotrexate suppresses NF-{kappa}B activation through inhibition of I{kappa}B{alpha} phosphorylation and degradation. J Immunol 167:2911–2920PubMed Majumdar S, Aggarwal BB (2001) Methotrexate suppresses NF-{kappa}B activation through inhibition of I{kappa}B{alpha} phosphorylation and degradation. J Immunol 167:2911–2920PubMed
23.
go back to reference Papadeas E, Naxakis S, Riga M et al (2007) Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. Eur J Oncol Nurs 11:60–65PubMedCrossRef Papadeas E, Naxakis S, Riga M et al (2007) Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. Eur J Oncol Nurs 11:60–65PubMedCrossRef
24.
go back to reference Pritchard DM, Jackman A, Potten CS et al (1998) Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity. Toxicol Lett 102–103:19–27PubMedCrossRef Pritchard DM, Jackman A, Potten CS et al (1998) Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity. Toxicol Lett 102–103:19–27PubMedCrossRef
25.
go back to reference Scully C, Epstein J, Sonis S (2003) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: Part 1, pathogenesis and prophylaxis of mucositis. Head Neck 25:1057–1070PubMedCrossRef Scully C, Epstein J, Sonis S (2003) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: Part 1, pathogenesis and prophylaxis of mucositis. Head Neck 25:1057–1070PubMedCrossRef
26.
go back to reference Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43PubMedCrossRef Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43PubMedCrossRef
27.
go back to reference Sonis ST (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 13:380–390PubMedCrossRef Sonis ST (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 13:380–390PubMedCrossRef
28.
go back to reference Sonis ST (2004) A biological approach to mucositis. J Support Oncol 2:21–36PubMed Sonis ST (2004) A biological approach to mucositis. J Support Oncol 2:21–36PubMed
29.
go back to reference Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025PubMedCrossRef Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025PubMedCrossRef
30.
go back to reference Taupin D, Podolsky DK (2003) Trefoil factors: Initiators of mucosal healing. Nat Rev Mol Cell Biol 4:721–732PubMedCrossRef Taupin D, Podolsky DK (2003) Trefoil factors: Initiators of mucosal healing. Nat Rev Mol Cell Biol 4:721–732PubMedCrossRef
31.
go back to reference Xu Y, Villalona-Calero MA (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841–1851PubMedCrossRef Xu Y, Villalona-Calero MA (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841–1851PubMedCrossRef
32.
go back to reference Yeoh ASJ, Bowen JM, Gibson RJ et al (2005) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 63:1295–1303PubMedCrossRef Yeoh ASJ, Bowen JM, Gibson RJ et al (2005) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 63:1295–1303PubMedCrossRef
Metadata
Title
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
Authors
Richard M. Logan
Andrea M. Stringer
Joanne M. Bowen
Rachel J. Gibson
Stephen T. Sonis
Dorothy M. K. Keefe
Publication date
01-01-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0732-8

Other articles of this Issue 2/2009

Cancer Chemotherapy and Pharmacology 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine